Association Between PD-L1/CD8 Expression and Outcomes in Melanoma Patients Who Received Dabrafenib/Trametinib

Video

Dirk Schadendorf, MD, professor, director, and chair of the clinic for dermatology at the University Hospital Essen in Germany, discusses the association between PD-L1 and CD8 expression and outcomes in patients with&nbsp;<em>BRAF V600E/K</em>-mutant metastatic melanoma who received dabrafenib (Tafinlar) plus trametinib (Mekinist) in the randomized phase III COMBI-v study.

Dirk Schadendorf, MD, professor, director, and chair of the clinic for dermatology at the University Hospital Essen in Germany, discusses the association between PD-L1 and CD8 expression and outcomes in patients withBRAF V600E/K

Related Videos
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Related Content
FDA Clears IND for Tumor Infiltrating Lymphocyte Therapy

FDA Clears IND for Tumor Infiltrating Lymphocyte Therapy

November 29th 2023
Article

A phase 1/2 study of KSQ-001EX will commence at MD Anderson Cancer Center following this investigational new drug approval from the FDA.

Read More

Understanding and Treating Mucosal Melanoma

Understanding and Treating Mucosal Melanoma

April 14th 2023
Podcast

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Listen

Behind the FDA Approval of Enzalutamide for Prostate Cancer

Behind the FDA Approval of Enzalutamide for Prostate Cancer

November 22nd 2023
Article

Neal Shore, MD, FACS, discussed the phase 3 EMBARK trial and what the FDA approval of enzalutamide means for the prostate cancer treatment landscape.

Read More

A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma

A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma

February 15th 2022
Podcast

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

Listen

Sotorasib and Panitumumab Outperforms SOC in KRAS G12C+ mCRC

Sotorasib and Panitumumab Outperforms SOC in KRAS G12C+ mCRC

November 15th 2023
Article

In an interview with Targeted Oncology, City of Hope cancer center’s Marwan Fakih, MD, further discussed the findings from this phase 3 trial and future directions for evaluating this combination.

Read More

Johnson Analyzes Combination Immunotherapy in the First Line in Advanced Melanoma

Johnson Analyzes Combination Immunotherapy in the First Line in Advanced Melanoma

November 15th 2023
Article

During a Targeted Oncology™ Case-Based Roundtable™ event, Douglas B. Johnson, MD, MSCI, reviewed data for safety and efficacy of immune checkpoint inhibition in patients with metastatic melanoma.

Read More